| |
Learn about populations at risk of HIV infection |
|
|
|
| |
HIV infection rates vary by patient population.1 How many patients in your practice are at risk of HIV infection?
|
|
| |
|
|
| |
IDENTIFY YOUR PATIENTS AT RISK |
|
| |
|
|
| |
| |
The Centers for Disease Control and Prevention (CDC) report these statistics estimating the number of people in the United States who will contract HIV in their lifetime.1,2
|
|
| |
| |
| MEN WHO HAVE SEX WITH MEN (MSM) |
| |
| Overall |
|
1 in 6 |
 |
| |
| African American |
|
1 in 2 |
 |
| |
| Hispanic/Latino |
|
1 in 4 |
 |
| |
| Caucasian |
|
1 in 11 |
 |
| |
|
|
| |
| |
| HETEROSEXUAL |
|
MEN |
|
WOMEN |
| |
| Overall |
|
1 in 473 |
|
1 in 241 |
| |
|
|
| |
| |
| OVERALL |
|
MEN |
|
WOMEN |
| |
| Overall |
|
1 in 64 |
|
1 in 227 |
| |
| African American |
|
1 in 20 |
|
1 in 48 |
| |
| Hispanic/Latino |
|
1 in 48 |
|
1 in 227 |
| |
| Caucasian |
|
1 in 132 |
|
1 in 880 |
| |
| Injection drug users |
|
1 in 36 |
|
1 in 23 |
| |
|
|
| |
| |
According to these CDC statistics, African American MSM and Hispanic/Latino MSM are at the highest risk of contracting HIV.1
|
|
| |
| |
The transgender community in the United States is also one of the highest-risk groups for HIV infection: an estimated 22% of transgender women are HIV positive.3
|
|
| |
| |
Although some patient populations may have a higher prevalence of HIV, it is critical to encourage prevention for all your patients.
|
|
| |
| |
|
|
| |
| |
By combining sexual history conversations, routine STI and HIV testing, condoms, and medication as appropriate, you can help protect your patients at risk of HIV infection.4,5
|
|
| |
| |
| |
| To learn more about HIV prevention, and to register for updates, visit |
|
|
|
| |
| |
| |
Thank you for your ongoing commitment to HIV prevention,
|
|
| |
| |
The Gilead HIV Prevention Team
|
|
| |
| |
References: 1. Centers for Disease Control and Prevention. 2016 Conference on Retroviruses and Opportunistic Infections. http://www.cdc.gov/nchhstp/newsroom/2016/croi-2016.html. Updated February 24, 2016. Accessed July 29, 2016. 2. Highleyman L. Major disparities persist in lifetime risk of HIV diagnosis in the US. https://www.aidsmap.com/Major-disparities-persist-in-lifetime-risk-of-HIV-diagnosis-in-the-US/page/3038645/. Published February 24, 2016. Accessed July 29, 2016. 3. Centers for Disease Control and Prevention. HIV among transgender people. https://www.cdc.gov/hiv/pdf/group/gender/transgender/cdc-hiv-transgender.pdf. Published 2016. Accessed July 29, 2016. 4. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States-2014: a clinical practice guideline. http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf. Published 2014. Accessed July 29, 2016. 5. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV-United States, 2016. https://stacks.cdc.gov/view/cdc/38856. Published 2016. Accessed July 29, 2016.
|
|
|
| |
| |
Gilead Website |
Terms of Use |
Privacy Policy |
Contact Us |
Unsubscribe
|
|
| |
| |
|
|
| |
| |
GILEAD, the GILEAD Logo, and the PreventHIV.com Logo are trademarks of Gilead Sciences, Inc., or one of its related companies.
© 2016 Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404
All rights reserved. UNBP2703 10/16
|
|
| |
